BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Envafolimab: trial readouts and FDA decisions
2 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 0 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: 3D Medicines (Sichuan) Co., Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P1/P2 | 3D Medicines (Sichuan) Co., Ltd. | NCT05024214 Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | Solid Tumors; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma | recruiting | 170 |
| 2026-12 est. | P2 | 3D Medicines (Sichuan) Co., Ltd. | NCT05112991 Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer | Advanced Endometrial Cancer | recruiting | 108 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| None in the last 180 days. | ||||||
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.